{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:15:48Z","timestamp":1790198148910,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100024218","name":"ARCAGY-GINECO","doi-asserted-by":"publisher","award":["Translational research Grant 2021"],"award-info":[{"award-number":["Translational research Grant 2021"]}],"id":[{"id":"10.13039\/100024218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Genom. Med."],"DOI":"10.1038\/s41525-026-00570-3","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:27:18Z","timestamp":1776943638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immuno-molecular features associated with exceptional recurrence\u2013free survivorship from Ovarian Cancer in the pre-PARP era"],"prefix":"10.1038","volume":"11","author":[{"given":"F\u00e9lix","family":"Blanc\u2013Durand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Yaniz Galende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gw\u00e9na\u00ebl","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Kalbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coriolan","family":"Lebreton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Zannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriak","family":"Blonz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Dohollou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Desauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Carola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Follana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Mourani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Le Formal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortense","family":"Gaultier De Saint Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Genestie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"570_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"570_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606. Ann. Oncol. 34, 833\u2013848 (2023).","journal-title":"Ann. Oncol."},{"key":"570_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000485618","volume":"83","author":"Y Xiao","year":"2017","unstructured":"Xiao, Y. et al. Platinum-based neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma International Federation of Gynecology and Obstetrics stages IIIc and IV: a systematic review and meta-analysis. Gynecol. Obstet. Investig. 83, 209\u2013219 (2017).","journal-title":"Gynecol. Obstet. Investig."},{"key":"570_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41416-022-01732-7","volume":"127","author":"B You","year":"2022","unstructured":"You, B. et al. Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. Br. J. Cancer 127, 79\u201383 (2022).","journal-title":"Br. J. Cancer"},{"key":"570_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann. Oncol. 34, 681\u2013692 (2023).","journal-title":"Ann. Oncol."},{"key":"570_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402 (2019).","journal-title":"N. Engl. J. Med."},{"key":"570_CR7","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl. J. Med."},{"key":"570_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/annonc\/mdz074","volume":"30","author":"F Joly","year":"2019","unstructured":"Joly, F. et al. Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case\/control VIVROVAIRE I study. Ann. Oncol. 30, 845\u2013852 (2019).","journal-title":"Ann. Oncol."},{"key":"570_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2023.01.008","volume":"170","author":"G Ferron","year":"2023","unstructured":"Ferron, G. et al. Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: lessons from the GINECO double-blind randomized phase II CHIVA trial. Gynecol. Oncol. 170, 186\u2013194 (2023).","journal-title":"Gynecol. Oncol."},{"key":"570_CR10","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1093\/bioinformatics\/btaa261","volume":"36","author":"A Eeckhoutte","year":"2020","unstructured":"Eeckhoutte, A. et al. ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. Bioinformatics 36, 3888\u20133889 (2020).","journal-title":"Bioinformatics"},{"key":"570_CR11","doi-asserted-by":"publisher","unstructured":"Blanc-Durand, F. et al. Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3328 (2023).","DOI":"10.1158\/1078-0432.CCR-22-3328"},{"key":"570_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova, O. et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat. Commun. 9, 3970 (2018).","journal-title":"Nat. Commun."},{"key":"570_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41568-019-0145-5","volume":"19","author":"FAM Saner","year":"2019","unstructured":"Saner, F. A. M. et al. Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nat. Rev. Cancer 19, 339\u2013348 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"570_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0590-x","volume":"10","author":"SYC Yang","year":"2018","unstructured":"Yang, S. Y. C. et al. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Med. 10, 81 (2018).","journal-title":"Genome Med."},{"key":"570_CR15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41588-022-01230-9","volume":"54","author":"DW Garsed","year":"2022","unstructured":"Garsed, D. W. et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat. Genet. 54, 1853\u20131864 (2022).","journal-title":"Nat. Genet."},{"key":"570_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1078-0432.CCR-17-1621","volume":"24","author":"DW Garsed","year":"2018","unstructured":"Garsed, D. W. et al. Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer. Clin. Cancer Res. 24, 569\u2013580 (2018).","journal-title":"Clin. Cancer Res."},{"key":"570_CR17","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1101\/gad.288282.116","volume":"30","author":"R V\u00e9lez-Cruz","year":"2016","unstructured":"V\u00e9lez-Cruz, R. et al. RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1. Genes Dev. 30, 2500\u20132512 (2016).","journal-title":"Genes Dev."},{"key":"570_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher, E. M. et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat. Commun. 12, 2487 (2021).","journal-title":"Nat. Commun."},{"key":"570_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcae033","volume":"6","author":"L Xu","year":"2024","unstructured":"Xu, L. et al. High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers. NAR Cancer 6, zcae033 (2024).","journal-title":"NAR Cancer"},{"key":"570_CR20","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.esmoop.2021.100144","volume":"6","author":"NYL Ngoi","year":"2021","unstructured":"Ngoi, N. Y. L. & Tan, D. S. P. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open 6, 100144 (2021).","journal-title":"ESMO Open"},{"key":"570_CR21","doi-asserted-by":"publisher","first-page":"1328651","DOI":"10.3389\/fimmu.2023.1328651","volume":"14","author":"F Blanc-Durand","year":"2023","unstructured":"Blanc-Durand, F., Clemence Wei Xian, L. & Tan, D. S. P. Targeting the immune microenvironment for ovarian cancer therapy. Front. Immunol. 14, 1328651 (2023).","journal-title":"Front. Immunol."},{"key":"570_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","volume":"124","author":"W-T Hwang","year":"2012","unstructured":"Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S. & Coukos, G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 124, 192\u2013198 (2012).","journal-title":"Gynecol. Oncol."},{"key":"570_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"570_CR24","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102, 18538\u201318543 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"570_CR25","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1158\/1078-0432.CCR-05-1244","volume":"11","author":"D Wolf","year":"2005","unstructured":"Wolf, D. et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11, 8326\u20138331 (2005).","journal-title":"Clin. Cancer Res."},{"key":"570_CR26","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/PAS.0b013e31825d9b8d","volume":"36","author":"M Fujiwara","year":"2012","unstructured":"Fujiwara, M. et al. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype. Am. J. Surg. Pathol. 36, 1170\u20131177 (2012).","journal-title":"Am. J. Surg. Pathol."},{"key":"570_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/modpathol.2008.191","volume":"22","author":"B Clarke","year":"2009","unstructured":"Clarke, B. et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 22, 393\u2013402 (2009).","journal-title":"Mod. Pathol."},{"key":"570_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/modpathol.2011.183","volume":"25","author":"RA Soslow","year":"2012","unstructured":"Soslow, R. A. et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod. Pathol. 25, 625\u2013636 (2012).","journal-title":"Mod. Pathol."},{"key":"570_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ygyno.2019.02.011","volume":"153","author":"CB Morse","year":"2019","unstructured":"Morse, C. B. et al. Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecol. Oncol. 153, 217\u2013222 (2019).","journal-title":"Gynecol. Oncol."},{"key":"570_CR30","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1158\/0008-5472.CAN-22-1821","volume":"83","author":"S Ferri-Borgogno","year":"2023","unstructured":"Ferri-Borgogno, S. et al. Spatial transcriptomics depict ligand\u2013receptor cross-talk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors. Cancer Res. 83, 1503\u20131516 (2023).","journal-title":"Cancer Res."},{"key":"570_CR31","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41588-025-02233-y","volume":"57","author":"JS Thompson","year":"2025","unstructured":"Thompson, J. S. et al. Predicting resistance to chemotherapy using chromosomal instability signatures. Nat. Genet. 57, 1708\u20131717 (2025).","journal-title":"Nat. Genet."}],"container-title":["npj Genomic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41525-026-00570-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-026-00570-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-026-00570-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:40:20Z","timestamp":1782718820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41525-026-00570-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1038\/s41525-026-00570-3","relation":{},"ISSN":["2056-7944"],"issn-type":[{"value":"2056-7944","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}